Did You Know?

Editor’s Picks

Latest News

Ascentage Pharma Announces Inclusion of Lisaftoclax in China’s 2026 National Reimbursement Drug List and Successful Renewal of Coverage for Olverembatinib

ROCKVILLE, Md., Nov. 15, 2026 (GLOBE NEWSWIRE) -- Ascentage Pharma Group International (NASDAQ: AAPG; HKEX: 6855), a global, commercial-stage, integrated...

Alpha Tau Announces New Positive Interim Results from its U.S. Alpha DaRT® Recurrent Glioblastoma Trial: All Patients Treated are Alive with Median Survival Not Reached, 6.9 Months Median Follow-Up in the First Six Evaluable Patients With 100% ORR, 100% Feasibility and No Unanticipated Serious Adverse Events – Conference Call Scheduled for 8:30am ET November 16

Helus Pharma to Present Topline Results from Phase 3 APPROACH Study Evaluating HLP003 as Adjunctive Treatment in Major Depressive Disorder on November 16, 2026

Attorney General Rescheduling Order Claimed State Marijuana Controls Were Robust. Oklahoma Law Enforcement Tells a Different Story

As MMJ International Holdings Challenges Marijuana Rescheduling in the D.C. Circuit, Oklahoma Narcotics Officials Describe Widespread Diversion and Enforcement Failures-Raising...

Cerenome Reports Third Quarter 2026 Financial Results and Business Highlights Featuring REYOBIQ ReSPECT- LM Data and CNSide Commercial and Reimbursement Progress

HOUSTON, Nov. 13, 2026 (GLOBE NEWSWIRE) -- Cerenome, Inc. (Nasdaq: CNSY) (“Cerenome” or the “Company”), a CNS oncology company advancing...

error: Content is protected !!